Trial Profile
Immunomodulatory effects of three tyrosine kinase inhibitors (dasatinib, imatinib and nilotinib) in patients with chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- 07 Sep 2016 New trial record